Skip to content
Biodatica
Start free

Replimune, Inc.

Iowa City, Iowa

OncologyPhase IIListed · REPL

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

3mo agoTrial registeredApr 2, 2026Source filing (opens the source filing in a new tab)

Momentum

72no change

Momentum 72 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Aug 1, 2024

    Hepatocellular Carcinoma, Biliary Tract Cancer · RECRUITING · sponsor: Replimune, Inc. · Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

    ClinicalTrials.gov · NCT05733598 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Dec 29, 2020

    Advanced Solid Tumor · ACTIVE_NOT_RECRUITING · sponsor: Replimune, Inc. · Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours

    ClinicalTrials.gov · NCT04735978 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources